Eledon Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ELDN Nasdaq 8731 https://eledon.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Eledon Pharmaceuticals Inc

Eledon Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 30, 2023 - Mar 23rd, 2023 8:05 pm
Eledon to Present Data from Ongoing Phase 1b Trial Evaluating Tegoprubart in Kidney Transplantation at the World Congress of Nephrology 2023 - Mar 23rd, 2023 12:00 pm
Eledon Pharmaceuticals to Present at SVB Securities Global Biopharma Conference - Feb 8th, 2023 9:05 pm
Eledon Pharmaceuticals Provides Business and Pipeline Updates - Jan 9th, 2023 1:31 pm
eGenesis and Eledon Pharmaceuticals Announce Collaboration for Use of Tegoprubart in Preclinical Xenotransplantation Studies - Jan 9th, 2023 1:30 pm
C-Path's Transplant Therapeutics Consortium Receives EMA Qualification Opinion for iBox Scoring System - Dec 21st, 2022 9:05 pm
Eledon Pharmaceuticals Reports Third Quarter 2022 Operating and Financial Results - Nov 14th, 2022 9:01 pm
Eledon Pharmaceuticals to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022 - Nov 3rd, 2022 8:05 pm
Eledon Pharmaceuticals Announces Upcoming Presentations at ASN’s Kidney Week 2022 and NEALS - Oct 24th, 2022 8:05 pm
Eledon Pharmaceuticals to Participate in Two Upcoming Conferences - Oct 3rd, 2022 12:00 pm
Eledon Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference - Sep 22nd, 2022 8:05 pm
Eledon Pharmaceuticals Receives FDA Clearance of IND Application to Evaluate Tegoprubart in IgA Nephropathy - Sep 6th, 2022 8:01 pm
Eledon Pharmaceuticals to Participate in Two Upcoming Investor Conferences - Aug 29th, 2022 12:00 pm
Eledon Pharmaceuticals Reports Second Quarter 2022 Operating and Financial Results - Aug 11th, 2022 8:01 pm
Eledon Pharmaceuticals to Report Second Quarter 2022 Financial Results on Thursday, August 11, 2022 - Aug 4th, 2022 8:05 pm
Eledon Pharmaceuticals Receives FDA Clearance of IND Application to Evaluate Tegoprubart for the Prevention of Rejection in Kidney Transplant Recipients - Aug 1st, 2022 9:00 am
Eledon Pharmaceuticals Announces the First Patient Dosed in Phase 1b Trial Evaluating Tegoprubart in Kidney Transplantation - Jul 18th, 2022 12:00 pm
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jun 10th, 2022 8:05 pm
Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Pancreatic Islet Cell Transplantation - Jun 9th, 2022 12:00 pm
Eledon Pharmaceuticals to Present at the Jefferies Healthcare Conference - Jun 2nd, 2022 8:05 pm